Abstract
Methods We set up a physician-directed questionnaire available on the website of CRI since January 2011 to December 2012, covering the following areas: patient data, disease data, anti-IL1 agent, its efficacy, adverse events. We advertised the study on the occasion of French rheumatology congresses and by email to French physicians that could be interested. Any adult or paediatric patient who had received an anti-IL1 agent before January 2005 in France could be included.
Highlights
Despite their limited licensed indications, anti-IL1 agents are often used in real-life practice for an increasing number of diseases
The survey is coordinated by the French National Reference Centre for Auto-Inflammatory Diseases, under the aegis of the “Club Rhumatisme et Inflammation” (CRI)
We set up a physician-directed questionnaire available on the website of CRI since January 2011 to December 2012, covering the following areas: patient data, disease data, anti-IL1 agent, its efficacy, adverse events
Summary
Despite their limited licensed indications, anti-IL1 agents are often used in real-life practice for an increasing number of diseases. Survey of off-label anti-IL1 treatments in France: preliminary data L Rossi-Semerano1*, B Fautrel2, C Galeotti1, I Koné-Paut1 From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
